Top 10 Abstracts at ESMO Breast 24 by Paolo Tarantino

Paolo Tarantino made the following post on LinkedIn:

“Less than 48h to ESMO Breast 24: time for the top 10 abstracts.

Highly awaited readout from IMpassion132, safety update of important phase 3 trials (TROPION-Breast01, NATALEE), safety of T-DXd rechallenge after G1 ILD, intriguing biomarker analyses from large datasets (HER2DX, monarchE) and much more.

Promises to be a terrific congress!”

Source: Paolo Tarantino/LinkedIn

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
OncoDaily
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.